Shares of Becton, Dickinson BDX moved higher by 0.0% in pre-market trading after the company reported Q1 results.
Quarterly Results
Earnings per share rose 71.70% over the past year to $4.55, which beat the estimate of $3.11.
Revenue of $5,315,000,000 higher by 25.80% from the same period last year, which beat the estimate of $4,880,000,000.
Guidance
The upcoming fiscal year's EPS expected to be between $12.75 and $12.85.
The upcoming fiscal year's revenue expected to be between $19,171,000,000 and $19,513,000,000.
Details Of The Call
Date: Feb 04, 2021
Time: 08:00 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/isdudxg2
Price Action
Company's 52-week high was at $286.72
Company's 52-week low was at $197.75
Price action over last quarter: Up 10.22%
Company Description
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
